Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users.
about
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportKyoto global consensus report on Helicobacter pylori gastritisGastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategiesPeptic ulcer disease todayInteraction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseasesSafe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksTreatment of Helicobacter pylori infection.Hematologic manifestations of Helicobacter pylori infectionContemporary Diagnostic Strategies for the Detection of Helicobacter pylori InfectionConsensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale.Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective.Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stoneAssessing the risks and benefits of treating Helicobacter pylori infection.Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance.Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis.The risk of upper gastrointestinal bleeding in patients treated with hemodialysis: a population-based cohort study.Eradication of Helicobacter pylori for the prevention of peptic ulcer rebleeding.American College of Gastroenterology guideline on the management of Helicobacter pylori infection.Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidanceInteraction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insightsRisk management of risk management: Combining proton pump inhibitors with low-dose aspirinHelicobacter pylori infection in bleeding peptic ulcer patients after non-steroidal antiinflammatory drug consumption.Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled triaCost Effectiveness Associated with Helicobacter pylori Screening and Eradication in Patients Taking Nonsteroidal Anti-Inflammatory Drugs and/or Aspirin.Helicobacter pylori: testing and treatment.Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations.Perforated peptic ulcer - an update.Assessment of the environmental risk factors for a gastric ulcer in northern GhanaPrevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review.Therapeutic management of recurrent peptic ulcer disease.Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database.Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection.3rd Brazilian Consensus on Helicobacter pylori.Helicobacter pylori infection in Europe: current perspectives.Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition.Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence.Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend?Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents.Management of NSAID-associated peptic ulcer disease.
P2860
Q24674636-C5DFF946-D6AE-402A-8FA3-C75265CCED1BQ26799430-69D33D49-3D14-4DA1-AAAD-0F2F814329B8Q27026351-EABBF19C-7708-4B7A-B131-1D5553261EA9Q28194844-209346BB-BBCE-4B42-8B51-9F8973CA6B51Q28219634-17B64BD1-E403-4636-9FA1-FC8D71D432EDQ30629677-8E7C0A3C-2BF4-4CF4-8EAB-5ECC18634A27Q33372344-C33F6610-A5D3-400E-88A9-32BA660E53C9Q33417972-132679BD-CEAD-4425-831F-E174DC792636Q33624655-83213B8C-7B92-49F1-B0BE-2248CC6830CDQ33698340-AD57C16F-8931-44C5-A607-4BE8AE39B176Q33960344-BBD6FF3B-2468-4E9E-B5EB-E75686C5C6BFQ34408895-787DCE48-73F0-418F-8F7A-A9E857DC4D9DQ34408985-99A67E8F-1C7C-46D9-91C3-1F26873C2767Q34448307-F4F0FA1D-838A-497E-A5BA-B812F322E61AQ34449825-BABC7969-5038-497C-91BA-0CA6D5754E43Q34550255-54862EDF-93FC-440B-AE8E-12D573C6A54DQ34581560-032F71CA-4910-44FF-943B-F8A248AC28F9Q34645482-8C392C8A-E02D-4485-8AF1-EF9D655BE7E0Q34655792-EE8C67F1-B2C3-4B72-8D06-07E22F6D0B1FQ34663572-10A0B3F4-2F0D-4B6F-8872-A64C8DFF26F1Q35026472-D12888C2-8088-42DD-8A22-1A1AD9AC3CBDQ35555697-5E56511B-79B7-4075-9085-0086BCFEFE17Q35989849-D45BA291-3EDD-4B52-A474-F7B1C77295EDQ36715136-22E9EBF9-5F3D-4842-B677-746E947A3910Q37346038-572E9CC5-436F-4FF2-8886-B1EEFFFC1ACFQ37358250-962937B6-18A9-4186-B78C-55081AE85DD4Q37587472-27C11D8C-25A2-4284-A302-8CD05DEC9D0AQ37666625-34BF4077-3578-4848-B167-5B3A7FA51EC9Q37893966-77D3E371-7269-4F74-AE5F-6572D4FA0810Q38001074-6D2A6469-34E9-44A5-BBB8-CE36526F0EA6Q38032319-FF67D813-475E-4578-9B68-80A0F61C4EE6Q38041462-6BDAA630-520B-4F49-A1CA-123287D1D26BQ38072783-1A705DE5-FFD4-4502-BE9E-BE8A7F6FD3CDQ38113105-9C6BCF65-815E-4690-BF39-7E08DB815A96Q38132278-8FA6CFB9-B234-4983-8A11-955E4701A5B0Q38206548-1245A04E-3CBB-42D9-80B2-ADC5C1A403EEQ38211000-FFAD1544-1D5D-4008-ABC4-AC50E5A449B7Q38541866-57AF68E4-59BA-4341-A05E-47B415F6EF87Q38578616-DF0298FA-9CD7-429D-834D-9ADD09DFAF44Q38699305-06275FB6-E135-424D-8BB9-28E843B47524
P2860
Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Meta-analysis: role of Helicob ...... f peptic ulcer in NSAID users.
@ast
Meta-analysis: role of Helicob ...... f peptic ulcer in NSAID users.
@en
type
label
Meta-analysis: role of Helicob ...... f peptic ulcer in NSAID users.
@ast
Meta-analysis: role of Helicob ...... f peptic ulcer in NSAID users.
@en
prefLabel
Meta-analysis: role of Helicob ...... f peptic ulcer in NSAID users.
@ast
Meta-analysis: role of Helicob ...... f peptic ulcer in NSAID users.
@en
P2093
P2860
P1476
Meta-analysis: role of Helicob ...... f peptic ulcer in NSAID users.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2036.2005.02444.X
P407
P577
2005-06-01T00:00:00Z